Intranasal versus subcutaneous rubella vaccination in schoolgirls.
In this study a venous blood specimen was drawn and, at the same time, rubella vaccine was given to 1906 schoolgirls mostly in the pre-pubertal age. To assess the pre-vaccination immune status and the effect of the vaccine, a  second  blood sample was taken 6 weeks later and tested for rubella HAI antibody simultaneously with the first one. RA 27/3 rubella vaccine administered by intranasal route to 81 girls produced a 100% seroconversion rate and the same vaccine strain, given by subcutaneous route to 460 girls,  produced a 94.73% seroconversion rate. Among the 1, 365 schoolgirls who received subcutaneous Cendehill vaccine, the seroconversion rate was 86.68%. Side effects were mild and transient and occurred, as headache, most frequently among the girls who received RA 27/3 vaccine by intranasal route.
D000281:Administration, Intranasal; D000293:Adolescent; D000914:Antibodies, Viral / Q000032:analysis; D002648:Child; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007279:Injections, Subcutaneous; D012409:Rubella / Q000517:prevention & control; D012411:Rubella Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D012412:Rubella virus / Q000276:immunology
D000914:Antibodies, Viral; D012411:Rubella Vaccine